Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

BACKGROUND: Treatment of breast cancer with aromatase inhibitors is associated with damage to bones. NCIC CTG MA.27 was an open-label, phase 3, randomised controlled trial in which women with breast cancer were assigned to one of two adjuvant oral aromatase inhibitors—exemestane or anastrozole. We p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Goss, Paul E, Hershman, Dawn L, Cheung, Angela M, Ingle, James N, Khosla, Sundeep, Stearns, Vered, Chalchal, Haji, Rowland, Kendrith, Muss, Hyman B, Linden, Hannah M, Scher, Judite, Pritchard, Kathleen I, Elliott, Catherine R, Badovinac-Crnjevic, Tanja, St Louis, Jessica, Chapman, Judith-Anne W, Shepherd, Lois E
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352316/
https://ncbi.nlm.nih.gov/pubmed/24636210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70035-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados